This synthesis page documents the complete causal chain from PSEN1 (Presenilin 1) genetic mutations to Alzheimer's disease phenotype, integrating genetic evidence, molecular mechanisms, cellular pathways, and therapeutic intervention points.
PSEN1 encodes Presenilin 1, the catalytic subunit of the gamma-secretase complex. It is the most common cause of autosomal dominant early-onset Alzheimer's disease (EOAD).
| Property |
Value |
| Chromosome |
14q24.3 |
| Protein |
Presenilin 1 (467 amino acids) |
| Function |
Aspartyl protease, gamma-secretase catalytic subunit |
| Inheritance |
Autosomal dominant |
| Age of Onset |
Typically 30-60 years (mean ~45) |
Over 300 pathogenic mutations in PSEN1 have been identified. The most well-characterized include:
| Mutation |
Location |
Effect |
Year Described |
| M146L |
TM2 |
γ-secretase hyperactivity |
1995 |
| L286V |
TM7 |
Aβ42/40 ratio increase |
1998 |
| A246E |
TM6 |
Altered APP processing |
1996 |
| H163Y |
TM4 |
Increased Aβ42 |
1997 |
| L173W |
TM4 |
Impaired gamma-secretase |
2001 |
| C410Y |
PALM |
Loss of function |
2004 |
| P436S |
PALM |
Impaired autophagy |
2018 |
- Causality strength: Absolutely proven - PSEN1 mutations are fully penetrant causes of autosomal dominant AD
- Population frequency: Very rare (<0.001% of population)
- Age of onset: Highly predictable (~45 years average)
- Segregation: Perfect Mendelian inheritance in affected families
PSEN1 is the catalytic core of the gamma-secretase complex, which includes:
flowchart TD
A["APP protein"] --> B["Alpha-secretase cleavage"]
A --> C["Beta-secretase BACE1"]
B --> D["sAPPalpha"]
C --> E["C99 fragment"]
E --> F["Gamma-secretase complex"]
F --> G["PSEN1 catalytic subunit"]
F --> H["APH1"]
F --> I["PEN2"]
F --> J["NCT"]
G --> K["A beta peptides"]
K --> L["Aβ40"]
K --> M["Aβ42"]
M --> N["Amyloid plaque formation"]
PSEN1 mutations alter the gamma-secretase cleavage pattern, leading to:
- Increased Aβ42/Aβ40 ratio - Most PSEN1 mutations increase the proportion of longer, more aggregation-prone Aβ42
- Altered cleavage position - Some mutations shift cleavage from γ-48/γ-43 to produce more Aβ42/Aβ43
- Reduced gamma-secretase activity - Some mutations impair overall protease function
- Endoplasmic reticulum stress - Mutant presenilin accumulates in ER, causing calcium dysregulation
flowchart TD
A["PSEN1 mutation"] --> B["Altered gamma-secretase activity"]
B --> C["Increased Aβ42/Aβ40 ratio"]
C --> D["Aβ42 oligomerization"]
D --> E["Synaptic toxicity"]
D --> F["Oxidative stress"]
D --> G["Mitochondrial dysfunction"]
E --> H["Synaptic loss"]
F --> I["ROS accumulation"]
G --> J["ATP depletion"]
H --> K["Cognitive decline"]
I --> K
J --> K
PSEN1 mutations contribute to synaptic failure through:
- Aβ-induced synaptic pruning - Oligomeric Aβ42 drives excessive NMDA receptor internalization
- Calcium dysregulation - ER calcium leak through mutant presenilin
- Synaptic protein trafficking - Altered vesicular trafficking to synapses
- Long-term potentiation impairment - Memory trace weakening
flowchart LR
subgraph Mitochondrial Pathway
A["Aβ42"] --> B["Mitochondrial complex IV inhibition"]
B --> C["Cytochrome c release"]
C --> D["Apoptosis activation"]
end
subgraph ER Stress Pathway
E["PSEN1 mutation"] --> F["ER stress"]
F --> G["UPR activation"]
G --> H["Caspase-12 activation"]
H --> D
end
subgraph Oxidative Stress
I["Aβ42"] --> J["ROS production"]
J --> K["DNA damage"]
K --> L["PARP activation"]
L --> D
end
D --> M["Neuronal Death"]
- Microglial activation - Aβ42 plaques trigger chronic neuroinflammation
- Astrocyte reactivity - Glial fibrillary acidic protein (GFAP) upregulation
- Neuroimmune axis - TREM2-expressing microglia attempt phagocytosis
| Stage |
Age |
Clinical Features |
| Preclinical |
30-40 |
Normal cognition, biomarker changes |
| Prodromal |
40-45 |
MCI, episodic memory deficits |
| Mild AD |
45-50 |
Working memory impairment, word-finding difficulty |
| Moderate AD |
50-55 |
Disorientation, behavioral changes |
| Severe AD |
55+ |
Global cognitive decline, motor symptoms |
PSEN1 mutations show significant phenotypic variation:
- Ataxia - Some mutations (e.g., P436S) cause cerebellar ataxia
- Myoclonus - Seizure-like muscle jerks common in later stages
- Language predominant - Some families show primary progressive aphasia
- Atypical parkinsonism - Rare cases with Lewy body pathology
| Intervention |
Mechanism |
Development Stage |
Target |
| Gamma-secretase modulators (GSMs) |
Shift cleavage to produce less Aβ42 |
Phase 2/3 |
Aβ42 production |
| Anti-Aβ antibodies |
Passive immunization against Aβ42 |
Phase 3 (lecanemab, donanemab) |
Aβ plaques |
| Aβ oligomer inhibitors |
Block toxic oligomer formation |
Preclinical |
Aβ42 oligomers |
| BACE inhibitors |
Prevent Aβ production upstream |
Halted (toxicity) |
BACE1 |
| PSEN1 correctors |
Restore normal gamma-secretase function |
Preclinical |
PSEN1 folding |
| Approach |
Strategy |
Challenges |
Timeline |
| ASO therapy |
Silence mutant PSEN1 allele |
Allele-specific targeting required |
5-10 years |
| CRISPR-Cas9 |
Correct mutation in neurons |
CNS delivery, off-target effects |
10+ years |
| Gene therapy |
Deliver wild-type PSEN1 |
Promiscuous gamma-secretase functions |
10+ years |
| Protein folding drugs |
Correct PSEN1 misfolding |
Small molecule delivery to brain |
5-10 years |
flowchart TD
subgraph Prevention
A["PSEN1 mutation carriers"] --> B["Lifestyle intervention"]
A --> C["Monitoring"]
end
subgraph Disease Modification
B --> D["Gamma-secretase modulators"]
C --> E["Anti-Aβ immunotherapy"]
D --> F["Reduce Aβ42 production"]
E --> G["Clear existing plaques"]
end
subgraph Symptomatic
F --> H["Slow progression"]
G --> H
end
style A fill:#ffcdd2
style H fill:#c8e6c9
| Category |
Score |
Rationale |
| Genetic Causality |
10/10 |
Fully penetrant, autosomal dominant, >300 mutations |
| Mechanism Validation |
9/10 |
Gamma-secretase complex well-characterized |
| Therapeutic Potential |
7/10 |
Multiple approaches in development, but gamma-secretase complexity is challenging |
| Clinical Translation |
8/10 |
Biomarkers available, clinical trials ongoing |
| Overall |
8.5/10 |
Strong evidence for causal chain |
- Early-onset familial AD: PSEN1 accounts for ~70% of FAD cases
- Late-onset AD modifier: PSEN1 variants may modify risk in LOAD
- Atypical AD: Some PSEN1 mutations cause posterior cortical atrophy
| Disease |
Connection |
Evidence |
| Parkinson's Disease |
PSEN1 affects alpha-synuclein processing |
Moderate |
| FTD |
Shared neuroinflammation pathways |
Moderate |
| ALS |
TDP-43 co-pathology in some cases |
Weak |
| Cerebral amyloid angiopathy |
Aβ42 vascular deposition |
Strong |
- Protein aggregation - Similar to α-synuclein (PD), TDP-43 (ALS)
- ER stress - Shared with ALS (C9orf72, SOD1)
- Mitochondrial dysfunction - Universal feature across neurodegenerative diseases
¶ Knowledge Gaps and Research Priorities
- Mechanism heterogeneity - Why do different PSEN1 mutations cause different phenotypes?
- Presenilin function - Non-amyloid functions of presenilin in neuronal health
- Therapeutic window - How to modulate gamma-secretase without causing Notch toxicity
- Biomarker validation - Which biomarkers best predict progression in PSEN1 carriers?
| Priority |
Research Area |
Rationale |
| 1 |
GSM development |
Nearest to clinical translation |
| 2 |
Biomarker discovery |
Essential for clinical trials |
| 3 |
Non-amyloid mechanisms |
May reveal new targets |
| 4 |
Gene therapy approaches |
Potential cure |
- Sherrington et al., Cloning of a novel gene bearing missense mutations in early onset familial Alzheimer's disease (1995)
- Ryman & Lamb, Presenilin-1 mutations in Alzheimer's disease: 30 years of insights into pathogenesis and therapeutic targeting (2023)
- De Strooper & Karchete, The physiology of gamma-secretase: implications for Alzheimer's disease (2022)
- Weggen & Shoemaker, PSEN1 mutations and gamma-secretase modulation (2021)
- Salloway et al., Anti-amyloid immunotherapy in PSEN1 carriers (2023)
- Cacquevel et al., Gamma-secretase modulators in clinical trials (2022)
- Shen & Kelleher, Presenilin-dependent gamma-secretase activity (2021)
- Early blood immune molecular alterations in cynomolgus monkeys with a PSEN1 mutation causing familial Alzheimer's disease (2024)
- APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease (2024)
- Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis (2024)
- Haploinsufficiency and Alzheimer's Disease: The Possible Pathogenic and Protective Genetic Factors (2024)
- Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer's disease profile (2024)
- Gene replacement-Alzheimer's disease (GR-AD): Modeling the genetics of human dementias in mice (2023)
- TRIM22 facilitates autophagosome-lysosome fusion by mediating the association of GABARAPs and PLEKHM1 (2023)
- Gamma-Secretase Modulator BPN15606 Reduced Abeta42 and Abeta40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome (2024)
- Gamma Secretase as an Important Drug Target for Management of Alzheimer's Disease: A Comprehensive Review (2023)
- Air pollution amyloidogenesis is attenuated by the gamma-secretase modulator GSM-15606 (2024)
- Discovery of Clinical Candidate PF-06648671: A Potent gamma-Secretase Modulator for the Treatment of Alzheimer's Disease (2024)
- Emerging structures and dynamic mechanisms of gamma-secretase for Alzheimer's disease (2024)
- PS1/gamma-secretase acts as rogue chaperone of glutamate transporter EAAT2/GLT-1 in Alzheimer's disease (2024)
- Presenilin-1 (PSEN1) Mutations: Clinical Phenotypes beyond Alzheimer's Disease (2023)
- The PSEN1 E280G mutation leads to increased amyloid-beta43 production in induced pluripotent stem cell neurons and deposition in brain tissue (2023)
- PSEN1 His214Asn Mutation in a Korean Patient with Familial EOAD and the Importance of Histidine-Tryptophan Interactions in TM-4 Stability (2024)
- A New Presenilin-1 Missense Variant Associated With a Progressive Supranuclear Palsy-like Phenotype (2023)